secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001376339-25-000104
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance
-----------------------------------------------------------------

- Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.
- Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.
- Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.
- 2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.
- CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/0001376339-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/mdxg-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001376339-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer